Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II paclitaxel polymer micelles plus gemcitabine in first-line advanced pancreatic cancer
ChiCTR2300077816Phase 2Recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of paclitaxel and gemcitabine in pancreatic adenocarcinoma (PDAC) and pancreatic cancer (PC) (2 arms), sponsored by Fudan University Shanghai Cancer Center. Primary endpoints: objective response rate and progression-free survival. Started Nov 2023; status: recruiting.
02
Drugs
paclitaxelgemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)pancreatic cancer (PC)
Beyond the preview
Go deeper on ChiCTR2300077816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300077816.